Toggle light / dark theme

Human Dementia Study: BioViva Analyzes the Data

I am pleased to share our most recent video on the “Dementia Safety Study” funded by Maximum Life Foundation and run by IHS, in which BioViva did the data analysis. This treatment shows promise for the millions of people who have dementia today. Though not a cure, it is a step in the right direction.


Can gene therapy delay or reverse Alzheimer’s and other dementias?

Want to learn more about BioViva? Visit: https://bioviva-science.com/

Interested in aging tests? https://bioviva-science.com/collections/products.

Facebook https://www.facebook.com/BiovivaScience.
Twitter https://twitter.com/BioVivaScience.
Instagram https://www.instagram.com/biovivascience.
LinkedIn https://www.linkedin.com/in/liz-parrish.

Study Find Links to Genetic Disorders in Walking Patterns

Summary: Researchers have linked Fragile X and SHANK3 deletion syndrome, two disorders associated with autism, to specific microscopic walking patterns.

Source: Rutgers.

Rutgers researchers have linked the genetic disorders Fragile X and SHANK3 deletion syndrome – both linked to autism and health problems – to walking patterns by examining the microscopic movements of those wearing motion-sensored sneakers.

Psilocybin Can Enhance How People Emotionally Connect to Music

Taking psilocybin can affect one’s emotional state when listening to music, according to new research presented earlier this month at the 34th ECNP Congress in Lisbon.

Psilocybin, the active psychedelic component of magic mushrooms, has previously shown great promise when used in therapy settings for the treatment of depression. Many of these clinical trials often make use of selected music playlists to support the subjective psychedelic experience felt by the trial participant.

Now, scientists believe that this action of combining psilocybin with music may result in enhanced emotional processing on behalf of the participant, implying that music should be treated as a more active component of psilocybin therapy.

Mike Graglia, Managing Dir & Co-Founder, SynGAP Research Fund — Collaboration, Transparency, Urgency

Collaboration, transparency & urgency for rare disease research — mike graglia, managing director & co-founder, syngap research fund — SRF.


Mike Graglia is the Managing Director & Co-Founder of the SynGAP Research Fund (SRF — https://www.syngapresearchfund.org/), an organization that he set up in 2018 with his wife Ashley, after their son was diagnosed with a rare neurological disease caused by an insufficiency in SynGAP protein, which causes the life-changing diagnoses of Epilepsy, Autism, sleep disorder and intellectual disability.

The mission of SRF is to improve the quality of life of SynGAP1 patients through the research and development of treatments, therapies and support systems.

Previously, Mike worked at the Emerson Collective, New America Foundation, the Bill and Melinda Gates Foundation, BCG, the World Bank/IFC and the US Peace Corps/Namibia. During his time in Africa he created a small charity to fund girls’ education.

Mike graduated from Gonzaga University with a BS in mathematics. He then attended the Johns Hopkins School of Advanced International Studies (SAIS) and Columbia Business School.

A diet of essential amino acids could keep dementia at bay, finds study

Protein intake is known to be vital for maintaining brain function in older individuals. Now, using a mouse model of Alzheimer’s disease, researchers have shown that the intake of a specific set of amino acids can inhibit the death of brain cells, protect the connections between them, and reduce inflammation, preserving brain function. Their research suggests that this amino acid combination called Amino LP7 can hinder the development of dementia, including Alzheimer’s disease.

No one knows why some people age worse than others and develop diseases-such as Alzheimer’s, fibrosis, type 2 diabetes or some types of cancer-associated with this aging process

One explanation for this could be the degree of efficiency of each organism’s response to the damage sustained by its cells during its life, which eventually causes them to age. In relation to this, researchers at the Universitat Oberta de Catalunya (UOC) and the University of Leicester (United Kingdom) have developed a new method to remove old cells from tissues, thus slowing down the aging process.

Researchers design antibodies that destroy old cells, slowing down aging

No one knows why some people age worse than others and develop diseases-such as Alzheimer’s, fibrosis, type 2 diabetes or some types of cancer-associated with this aging process. One explanation for this could be the degree of efficiency of each organism’s response to the damage sustained by its cells during its life, which eventually causes them to age. In relation to this, researchers at the Universitat Oberta de Catalunya (UOC) and the University of Leicester (United Kingdom) have developed a new method to remove old cells from tissues, thus slowing down the aging process.

Specifically, they have designed an antibody that acts as a smart bomb able to recognize specific proteins on the surface of these aged or senescent . It then attaches itself to them and releases a drug that removes them without affecting the rest, thus minimizing any potential side effects.

The results of this work, which have been published in Scientific Reports, open the door to the development of effective treatments to delay the progress of age-related diseases and even the aging process itself in the longer term, with the aim of increasing the longevity and, above all, the quality of life of people at this stage of their lives.

Anti-amyloid antibody receives Breakthrough Therapy Designation in US

Roche’s gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration in Alzheimer’s disease patients.

Roche’s gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD).

Brain-Computer Interfaces Evolve to Help People With Paralysis

BCIs stands out as one of the most promising assistive technologies.

Full Story:


All your movements start out in your brain.

When you decided that you wanted to read this article, you planned on moving your finger (or your cursor) toward a certain spot on your screen. Without noticing it, you thought about pressing or clicking on that spot. After quickly processing that thought, your brain told your muscles to respond to it accordingly, and here you are.

But the muscles of people with paralysis do not react to these brain signals. The brain might be unable to send the signals, the spinal cord might fail to deliver them to the nerves, or the nerves might not respond to them. This can be due to congenital or acquired damage in any of these parts of the nervous system.

Alzheimer’s Mystery Solved: How Amyloid Beta Forms in Brain Nerve Cells

Only a matter of time til we can have nanobots clearing this out.


In a major breakthrough, researchers at Massachusetts General Hospital (MGH) have discovered how amyloid beta — the neurotoxin believed to be at the root of Alzheimer’s disease (AD) — forms in axons and related structures that connect neurons in the brain, where it causes the most damage. Their findings, published in Cell Reports, could serve as a guidepost for developing new therapies to prevent the onset of this devastating neurological disease.

Among his many contributions to research on AD, Rudolph Tanzi, PhD, vice chair of Neurology and co-director of the McCance Center for Brain Health at MGH, led a team in 1986 that discovered the first Alzheimer’s disease gene, known as APP, which provides instructions for making amyloid protein precursor (APP). When this protein is cut (or cleaved) by enzymes — first, beta secretase, followed by gamma secretase — the byproduct is amyloid beta (sometimes shortened to Abeta). Large deposits of amyloid beta are believed to cause neurological destruction that results in AD. Amyloid beta formed in the brain’s axons and nerve endings causes the worst damage in AD by impairing communication between nerve cells (or neurons) in the brain. Researchers around the world have worked intensely to find ways to block the formation of amyloid beta by preventing cleavage by beta secretase and gamma secretase. However, these approaches have been hampered by safety issues.

Despite years of research, a major mystery has remained. “We knew that Abeta is made in the axons of the brain’s nerve cells, but we didn’t know how,” says Tanzi. He and his colleagues probed the question by studying the brains of mice, as well as with a research tool known as Alzheimer’s in a dish, a three-dimensional cell culture model of the disease created in 2014 by Tanzi and a colleague, Doo Yeon Kim, PhD. Earlier, in 2,013 several other MGH researchers, including neurobiologist Dora Kovacs, PhD (who is married to Tanzi), and Raja Bhattacharyya, PhD, a member of Tanzi’s lab, showed that a form of APP that has undergone a process called palmitoylation (palAPP) gives rise to amyloid beta. That study indicated that, within the neuron, palAPP is transported in a fatty vesicle (or sac) known as a lipid raft. But there are many forms of lipid rafts.

/* */